Insulin aspart is named as an intervention in 2 current clinical trials in our USA and China registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novo Nordisk A/S (1). The most-studied condition is Diabetes Mellitus, Type 1.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308 · ClinicalTrials.gov ↗ · Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
|
Not applicable | Recruiting | Beijing Hospital | China |
|
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 1
|
Phase 3 | Active, closed | Novo Nordisk A/S | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
16 single-substance products containing Insulin aspart on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 1 |
| Beijing Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and China registers name Insulin aspart as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novo Nordisk A/S (1) and Beijing Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 16 single-substance products containing Insulin aspart, for example Dazparda 100 units/ml solution for injection in pre-filled pen (Gan & Lee Pharmaceuticals Europe GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 4 entries for Insulin aspart: Fiasp PumpCart (insulin aspart) (EU: shortage ongoing); NovoRapid PumpCart (insulin aspart) (EU: shortage ongoing); 2 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Insulin aspart works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Insulin aspart works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Insulin aspart (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.